The company’s primary insurance division remains the core engine of this expansion, reporting a 74.1% increase in related income compared to last year. Waterdrop is aggressively embedding artificial intelligence into its value chain; the user-facing 'AI Insurance Expert' saw a 17.7% quarter-over-quarter rise in facilitated premiums. Furthermore, the firm is leveraging big data to broaden coverage for individuals with pre-existing conditions, a segment that saw a 24.3% boost in premiums this quarter.

Beyond insurance, Waterdrop’s Medical Crowdfunding platform continues its decade-long mission, having facilitated RMB73.5 billion in donations from 494 million users for 3.75 million patients. To improve efficiency, the company introduced an AI fundraising assistant that has already supported over 82,000 campaigns. Simultaneously, the E-Find clinical trial platform generated RMB24.2 million in revenue, supported by a network of 243 pharmaceutical partners and CROs. As of May 31, 2026, the company has repurchased approximately 61.8 million American Depositary Shares, reflecting a strategy to return value to shareholders while scaling its digital health infrastructure.